

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of.: Schacht, D.W. *et al.*  
Serial No.: **10/623,864**  
Filed: 22 July 2003  
Title: TRANSDERMAL DELIVERY SYSTEM FOR THE  
ADMINISTRATION OF ROTIGOTINE  
Group Art Unit: 1611  
Examiner: C.E. Rae  
Confirmation No.: 6414  
Docket No.: **6102-000069/US**  
Client Ref.: P/Wo/VII/10/02

**SUBMITTED ELECTRONICALLY VIA EFS-WEB**

24 September 2009

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

REQUEST FOR CONTINUED EXAMINATION UNDER 37 C.F.R. §1.114  
(INCLUDING SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.97(b)(4))

This paper is in response to the Final Office Action dated 24 June 2009 in which a shortened statutory period of three months was set for reply. Applicant hereby submits a request for continued examination (RCE). Authorization is provided herewith to charge the fee due under 37 C.F.R. §1.17(e) to Deposit Account No. **08-0750**.

The following claims are now pending in the present application: Claims 1–13. Claim 7 is withdrawn for examination purposes as being directed to non-elected subject matter. No claims are amended in the present reply. The pending claims are the same as those amended on 15 February 2008.